UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2015
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________to _________
Commission file number: 0-21419
Tiger X Medical, Inc.
|
|
|
|
|
|
2934½ Beverly Glen Circle, Suite #203
Los Angeles, CA 90077
(310) 987-7345
N/A
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):
|
Large accelerated filer ¨ |
Accelerated filer ¨ |
Non-accelerated filer ¨
|
Smaller reporting company x |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
As of August 12, 2015, 230,293,141 shares of the issuer's common stock, par value of $0.001 per share, were outstanding.
TIGER X MEDICAL, INC.
Table of Contents Page PART I — FINANCIAL INFORMATION 1 Item 1. 1 1 2 3 4 Item 2. 6 Item 3. 9 Item 4. 9 PART II — OTHER INFORMATION 11 Item 1. 10 Item 2. 10 Item 3. 10 Item 4. 10 Item 5. 10 Item 6. 11 12 Exhibit Index i
PART I — FINANCIAL INFORMATION ITEM 1 — CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
TIGER X MEDICAL, INC.
The accompanying notes are an integral part of these condensed consolidated financial statements.
1
The accompanying notes are an integral part of these condensed consolidated financial statements.
2
TIGER X MEDICAL, INC.
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
TIGER X MEDICAL, INC. NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Tiger X Medical, Inc. ("Tiger X" or the "Company"), formerly known as Cardo Medical, Inc., a corporation organized and existing under and by the virtue of the General
Corporation Law of the State of Delaware, previously operated as an orthopedic medical device company specializing in designing, developing and marketing high performance
reconstructive joint devices and spinal surgical devices. During 2010, the Company discontinued its operations and sold the assets from its previous business lines during 2011. Our continuing operations include the collection and
management of our royalty income earned in connection with the Asset Purchase Agreement with Arthrex, Inc. ("Arthrex"). We continue to advance and promote our former knee
product lines through participation in mobile teaching labs, seminars and live surgery. The Company is constantly evaluating opportunities for a suitable joint venture partner or buyer
for the remaining intellectual property owned by the Company. The Company is also evaluating investment opportunities and uses for its cash. Basis of Presentation The accompanying condensed consolidated balance sheet as of December 31, 2014, which has been derived from the Company's audited financial statements as of
that date, and the unaudited condensed consolidated financial information of the Company as of June 30, 2015 and for the three and six months ended June 30, 2015 and 2014, has
been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions
to Form 10-Q and Article 8-03 of Regulation S-X. In the opinion of management, such financial information includes all adjustments considered necessary for a fair presentation of
the Company's financial position at such date and the operating results and cash flows for such periods. Operating results for the interim period ended June 30, 2015 are not
necessarily indicative of the results that may be expected for the entire year. Certain information and footnote disclosure normally included in financial statements in accordance with generally accepted accounting principles have been omitted pursuant to
the rules of the United States Securities and Exchange Commission ("SEC"). These unaudited financial statements should be read in conjunction with our audited financial
statements and accompanying notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 filed on March 24, 2015. Principles of Consolidation The condensed consolidated financial statements include the accounts of Tiger X Medical, Inc., Accelerated Innovation, Inc. ("Accelerated"), Uni-Knee LLC ("Uni") and
Cervical Xpand LLC ("Cervical"). All significant intercompany transactions have been eliminated in consolidation. Royalty Agreement On January 24, 2011, the Company entered into an Asset Purchase Agreement with Arthrex (the agreement being the "Arthrex Asset Purchase Agreement"), pursuant
to which the Company agreed to sell the assets of the Reconstructive Division to Arthrex. The Arthrex Asset Purchase Agreement also provides for the Company to receive royalty
payments equal to 5% of net sales of the Company's products made by Arthrex on a quarterly basis for a term up to and including the 20th anniversary of the closing date. During
the three months ended June 30, 2015 and 2014, the Company received total royalty payments of $125,000 and $105,000, respectively, from Arthrex. During the six months ended
June 30, 2015 and 2014, the Company received total royalty payments of $261,000 and $203,000, respectively, from Arthrex. 4
These amounts are reflected as royalty income on the accompanying condensed consolidated statements of income. Use of Estimates Financial statements prepared in accordance with U.S. GAAP require management to make estimates and assumptions that affect the reported amounts of assets and
liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Among other things, management makes estimates
relating to share-based payments and deferred income tax assets. Actual results could differ from those estimates. Revenue Recognition The Company's revenue consists of royalty income from Arthrex pursuant to the Arthrex Asset Purchase Agreement. Royalty income is recognized as the amount
becomes known and collectability is reasonably assured. Net Income Per Share Basic net income per share is computed by using the weighted-average number of common shares outstanding during the period. Diluted net income per share is
computed giving effect to all dilutive potential common shares using various methods such as the treasury stock or modified treasury stock method in the determination of diluted
shares outstanding at each reporting period. Dilutive potential common shares consist of incremental common shares issuable upon exercise of stock options. No dilutive potential
common shares are included in the computation of any diluted per share amount because their impact was anti-dilutive. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards.
Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be
recovered or settled. The likelihood of realizing the tax benefits related to a potential deferred tax asset is evaluated, and a valuation allowance is recognized to reduce that deferred
tax asset if it is more likely than not that all or some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are calculated at the beginning and end of
the year; the change in the sum of the deferred tax asset, valuation allowance and deferred tax liability during the year generally is recognized as a deferred tax expense or benefit.
The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. The Company evaluates the accounting for uncertainty in income tax recognized in its financial statements and determines whether it is more likely than not that a tax position
will be sustained upon examination by the appropriate taxing authorities before any part of the benefit is recorded in its financial statements. For those tax positions where it is "not
more likely than not" that a tax benefit will be sustained, no tax benefit is recognized. Where applicable, associated interest and penalties are also recorded. The Company has not
accrued for any such uncertain tax positions as of June 30, 2015 (unaudited) or December 31, 2014. Concentration of Credit Risk The cash and cash equivalents held in the Company's business money market and other bank accounts are with local and national banking institutions and subjected to
FDIC insurance limits of $250,000 per banking institution. As of June 30, 2015, the Company's balances in these bank accounts exceeded the insured amount by $13,446,000. 5
Recent Accounting Pronouncements There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results
of operations, or cash flows. NOTE 2 - SHARE BASED PAYMENT The Company has outstanding stock options issued to employees and Board members which are exercisable at $0.23 per share. The options vest 20% each year over a
five year period and expire after ten years. As of June 30, 2015, there were no unvested options. There was no stock option expense recognized for the three or six months ended
June 30, 2015 or 2014 in the accompanying condensed consolidated statements of income. A summary of stock option activity as of June 30, 2015, and changes during the period then ended is presented below. NOTE 3 - STOCKHOLDERS' EQUITY Our authorized capital consists of 750,000,000 shares of common stock and 50,000,000 shares of preferred stock. Our preferred stock may be designated into series
pursuant to authority granted by our Certificate of Incorporation, and on approval from our Board of Directors. As of June 30, 2015 and December 31, 2014, we did not have any
preferred stock issued. ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The discussion and analysis of our financial condition and results of operations are based on our financial statements, which we have prepared in accordance with
accounting principles generally accepted in the United States of America. The preparation of these condensed consolidated financial statements requires us to make estimates and
assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial
statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate estimates and judgments, including those described in
greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates
under different assumptions or conditions. 6
As used in this "Management's Discussion and Analysis of Financial Condition and Results of Operation," except where the context otherwise requires, the term "we," "us," "our"
or "Tiger X" refers to the business of Tiger X Medical, Inc. The following discussion should be read together with the information contained in the unaudited condensed consolidated financial statements and related notes included
in Item 1, "Financial Statements," in this Form 10-Q. Overview Tiger X Medical, Inc. ("Tiger X" or the "Company"), formerly known as Cardo Medical, Inc., previously operated as an orthopedic medical device company specializing in
designing, developing and marketing high performance reconstructive joint devices and spinal surgical devices. During 2010, the Company discontinued its operations and sold the
assets from its previous business lines during 2011. Beginning on January 1, 2013, the Company became classified as a development stage entity. Our continuing operations
include the collection and management of our royalty income earned in connection with the Asset Purchase Agreement with Arthrex. We continue to advance and promote our
former knee product lines through participation in mobile teaching labs, seminars and live surgery. The Company is constantly evaluating opportunities for a suitable joint venture
partner or buyer for the remaining intellectual property owned by the Company. The Company is also evaluating investment opportunities and uses for its cash. We are headquartered in Los Angeles, California. Our common stock is quoted on the National Association of Securities Dealers, Inc.'s, Over-the-Counter Bulletin Board, or the
OTC Bulletin Board with a trading symbol of CDOM.OB. Critical Accounting Policies Use of Estimates Financial statements prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") require management to make estimates and
assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting
period. Among other things, management makes estimates relating to share-based payments, and deferred income tax assets. Given the short operating history of Tiger X, actual
results could differ from those estimates. Royalty Agreement On January 24, 2011, the Company entered into an Asset Purchase Agreement with Arthrex (the agreement being the "Arthrex Asset Purchase Agreement"), pursuant
to which the Company agreed to sell the assets of the Reconstructive Division to Arthrex. The Arthrex Asset Purchase Agreement also provides for the Company to receive royalty
payments equal to 5% of net sales of the Company's products made by Arthrex on a quarterly basis for a term up to and including the 20th anniversary of the closing date. During
the three months ended June 30, 2015 and 2014, the Company received total royalty payments of $125,000 and $105,000, respectively, from Arthrex. During the six months ended
June 30, 2015 and 2014, the Company received total royalty payments of $261,000 and $203,000, respectively, from Arthrex. These amounts are reflected as royalty income on the
accompanying condensed consolidated statements of income. Revenue Recognition The Company's revenue consists of royalty income from Arthrex pursuant to the Arthrex Asset Purchase Agreement. Revenue is recognized as the amount becomes
known and collectability is reasonably assured. 7
Recent Accounting Pronouncements There are no recently issued accounting pronouncements that we have yet to adopt that are expected to have a material effect on our financial position, results of
operations, or cash flows. Results of Operations for the Three Months Ended June 30, 2015 as Compared to the Three Months Ended June 30, 2014. The following is a comparison of the condensed consolidated results of operations for Tiger X for the three months ended June 30, 2015 and 2014. Royalty income Royalty income amounted to $125,000 for the quarter ended June 30, 2015 as compared to $105,000 for the quarter ended June 30, 2014. Revenues represented
royalties received from Arthrex in connection with the Arthrex Asset Purchase Agreement. The increase during 2015 is the result of Arthrex's increased sales of the acquired product
line. Until we find a joint venture partner or buyer for our remaining intellectual property or find an investment opportunity for our existing cash, we expect our primary source of
revenue to be royalty payments under the Arthrex Asset Purchase Agreement. General and Administrative Expenses General and administrative expenses for the quarter ended June 30, 2015 increased by $13,000 as compared to the same period in 2014 due primarily to increased
professional expenses during the quarter ended June 30, 2015. General and administrative expenses primarily represent our continuing operating expenses, including business
insurance expense and professional fees such as legal, accounting and audit services. Interest Income Our interest income remained consistent for to the quarters ended June 30, 2015 and 2014 due to our cash levels remaining consistent. We had no interest expense in
2015 or 2014, as there was no debt outstanding during this timeframe. 8
Results of Operations for the Six Months Ended June 30, 2015 as Compared to the Six Months Ended June 30, 2014. The following is a comparison of the condensed consolidated results of operations for Tiger X for the six months ended June 30, 2015 and 2014. Royalty income Royalty income amounted to $261,000 for the six months ended June 30, 2015 as compared to $203,000 for the six months ended June 30, 2014. Revenues
represented royalties received from Arthrex in connection with the Arthrex Asset Purchase Agreement. The increase during 2015 is the result of Arthrex's increased sales of the
acquired product line. Until we find a joint venture partner or buyer for our remaining intellectual property or find an investment opportunity for our existing cash, we expect our
primary source of revenue to be royalty payments under the Arthrex Asset Purchase Agreement. General and Administrative Expenses General and administrative expenses for the six months ended June 30, 2015 increased by $39,000 as compared to the same period in 2014 due primarily to increased
professional expenses during the six months ended June 30, 2015. General and administrative expenses primarily represent our continuing operating expenses, including business
insurance expense and professional fees such as legal, accounting and audit services. Interest Income Our interest income remained consistent for to the six months ended June 30, 2015 and 2014 due to our cash levels remaining consistent. We had no interest expense
in 2015 or 2014, as there was no debt outstanding during this timeframe. Liquidity and Capital Resources Net cash provided by operating activities was $179,000 for the six months ended June 30, 2015 compared to net cash provided by operating activities of $106,000 for the
same period in 2014. The change between the six months ended June 30, 2015 and the same period in 2014 was primarily due to an increase in our net income for the periods of
$19,000, as well as a decrease in prepaid expenses and other current assets of $27,000 during the six months ended June 30, 2015 compared to an increase of $7,000 for the
same period in 2014. Our accounts payable and accrued expenses also increased by $3,000 during the six months ended June 30, 2015 compared to a reduction of $17,000 for the
same period in 2014. 9
We had no cash flows from investing or financing activities during the six months ended June 30, 2015 or 2014. We believe our cash and cash equivalents as of June 30, 2015 are adequate to meet our cash needs for the next twelve months and beyond. Forward-Looking Statements Some of the statements in this Quarterly Report on Form 10-Q are "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of
1995. Forward-looking statements may be identified by the use of words such as "may," "will," "should," "anticipate," "estimate," "expect," "plan," "believe," "predict," "potential,"
"project," "target," "forecast," "intend," "assume," "guide," "seek" and similar expressions. Forward-looking statements do not relate strictly to historical or current matters. Rather,
forward-looking statements are predictive in nature and may depend upon or refer to future events, activities or conditions. Although we believe that these statements are based
upon reasonable assumptions, we cannot provide any assurances regarding future results. We undertake no obligation to revise or update any forward- looking statements, or to
make any other forward-looking statements, whether as a result of new information, future events or otherwise. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties. Many factors could cause
our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. Information regarding our risk factors appears in Part I, Item
1A, "Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, 2014 filed on March 24, 2015. ITEM 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Not applicable for smaller reporting companies. ITEM 4 - CONTROLS AND PROCEDURES Evaluation of Disclosure Controls and Procedures We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act,
that are designed to ensure that information required to be disclosed in our reports under the Exchange Act, is recorded, processed, summarized and reported within the time
periods specified in the Commission's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and
our interim principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. We carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and interim principal financial officer, of
the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d- 15(e) under the Exchange Act) as of the end of the period covered by this
quarterly report. Based on this evaluation, our Chief Executive Officer and interim Chief Financial Officer concluded that our disclosure controls and procedures were effective as of
June 30, 2015. Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June
30, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 10
PART II - OTHER INFORMATION We know of no material, existing or pending legal proceeding against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of
our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest. ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS None ITEM 3 - DEFAULTS UPON SENIOR SECURITIES None ITEM 4 - MINE SAFETY DISCLOSURES Not applicable None The following exhibits are filed as part of, or incorporated by reference into this Report: Exhibit Exhibit Title 31.1 Certification of Chief Executive Officer of Tiger X Medical, Inc., as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 * 31.2 Certification of Chief Financial Officer of Tiger X Medical, Inc., as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 * 32.1 Certification of Chief Executive Officer of Tiger X Medical, Inc. pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 * 32.2 Certification of Chief Financial Officer of Tiger X Medical, Inc. pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 * 101.INS* XBRL Instance Document 101.SCH* XBRL Taxonomy Extension Schema Document 101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF* XBRL Taxonomy Extension Definition Linkbase Document 101.LAB* XBRL Taxonomy Extension Label Linkbase Document 101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document * Filed herewith 11
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be
signed on its behalf by the undersigned thereunto duly authorized. TIGER X MEDICAL, INC. August 12, 2015 By: /s/ Andrew A. Brooks Andrew A. Brooks Chief Executive Officer and Interim Chief Financial Officer (Principal Financial and Accounting Officer)
YES ¨
NO x
Financial Statements
Condensed Consolidated Balance Sheets at June 30, 2015 (Unaudited) and
December 31, 2014
Condensed Consolidated Statements of Income (Unaudited) —
Three and Six Months Ended June 30, 2015 and 2014
Condensed Consolidated Statements of Cash
Flows (Unaudited) — Six Months Ended June 30, 2015 and 2014
Notes to Condensed Consolidated Financial Statements (Unaudited)
Management's Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Controls and Procedures
Legal Proceedings
Exhibits
Signatures
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts)
June 30,
December 31,
2015
2014
(Unaudited)
Assets
Current assets
Cash
$
13,688
$
13,509
Prepaid expenses and other current assets
9
36
Total assets
$
13,697
$
13,545
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable and accrued expenses
$
4
$
1
Total liabilities
4
1
Stockholders' equity
Common stock, $0.001 par value, 750,000,000 shares authorized, 230,293,141 shares issued and outstanding as of
June 30, 2015 (unaudited) and December 31, 2014, respectively
230
230
Additional paid-in capital
25,768
25,768
Accumulated deficit
(12,305)
(12,454)
Total stockholders' equity
13,693
13,544
Total liabilities and stockholders' equity
$
13,697
$
13,545
Three Months Ended
Six Months Ended
June 30,
June 30,
2015
2014
2015
2014
Royalty income
$
125
$
105
$
261
$
203
General and administrative expenses
53
40
114
75
Income from operations
72
65
147
128
Interest income
1
1
2
2
Income before income tax provision
73
66
149
130
Provision for income taxes
-
-
-
-
Net income
$
73
$
66
$
149
$
130
Net income per share:
Basic and diluted
$
-
$
-
$
-
$
-
Weighted average shares outstanding:
Basic and diluted
230,293,141
230,293,141
230,293,141
230,293,141
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
Six Months Ended
June 30,
2015
2014
Cash flows from operating activities
Net income
$
149
$
130
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
27
(7)
Accounts payable and accrued expenses
3
(17)
Net cash provided by operating activities
179
106
Net change in cash
179
106
Cash, beginning of period
13,509
13,295
Cash, end of period
$
13,688
$
13,401
Supplemental disclosure of cash flow information:
Interest paid
$
-
$
-
Income taxes paid
$
-
$
-
Notes to Condensed Consolidated Financial Statements
June 30, 2015
(Unaudited)
Weighted-
Weighted-
Average
Average
Remaining
Aggregate
Exercise
Contractual
Intrinsic
Options
Price
Life (Years)
Value
Outstanding at December 31, 2014
385,000
$
0.23
3.66
$
-
Granted
-
-
-
-
Exercised
-
-
-
-
Forfeited
-
-
-
-
Outstanding at June 30, 2015 (unaudited)
385,000
$
0.23
3.17
$
-
Vested and expected to vest
at June 30, 2015 (unaudited)
385,000
$
0.23
3.17
$
-
Exercisable at June 30, 2015 (unaudited)
385,000
$
0.23
3.17
$
-
Three Months Ended
June 30,
(In thousands)
2015
2014
$ Change
Royalty income
$
125
$
105
$
20
General and administrative expenses
53
40
13
Income from operations
72
65
7
Interest income
1
1
-
Income before income tax provision
73
66
7
Provision for income taxes
-
-
-
Net income
$
73
$
66
$
7
Six Months Ended
June 30,
(In thousands)
2015
2014
$ Change
Royalty income
$
261
$
203
$
58
General and administrative expenses
114
75
39
Income from operations
147
128
19
Interest income
2
2
-
Income before income tax provision
149
130
19
Provision for income taxes
-
-
-
Net income
$
149
$
130
$
19
Number
(Principal Executive Officer)
12
INDEX TO EXHIBITS
|
Exhibit |
Exhibit Title |
|
|
31.1 |
||
|
31.2 |
||
|
32.1 |
||
|
32.2 |
||
|
101.INS* |
XBRL Instance Document |
|
|
101.SCH* |
XBRL Taxonomy Extension Schema Document |
|
|
101.CAL* |
XBRL Taxonomy Extension Calculation Linkbase Document |
|
|
101.DEF* |
XBRL Taxonomy Extension Definition Linkbase Document |
|
|
101.LAB* |
XBRL Taxonomy Extension Label Linkbase Document |
|
|
101.PRE* |
XBRL Taxonomy Extension Presentation Linkbase Document |
|
|
* |
Filed herewith |
Exhibit 31.1
CERTIFICATION
I, Andrew A. Brooks, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Tiger X Medical, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
Date: August 12, 2015 |
/s/ Andrew A. Brooks Andrew A. Brooks Chief Executive Officer |
Exhibit 31.2
CERTIFICATION
I, Andrew A. Brooks, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Tiger X Medical, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
Date: August 12, 2015 |
/s/ Andrew A. Brooks Andrew A. Brooks Interim Chief Financial Officer |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Tiger X Medical, Inc. (the "Company") for the quarterly period ended June 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Andrew A. Brooks, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
/s/ Andrew A. Brooks Andrew A. Brooks Chief Executive Officer |
Date: August 12, 2015
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Tiger X Medical, Inc. (the "Company") for the quarterly period ended June 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Andrew A. Brooks, Interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
/s/ Andrew A. Brooks Andrew A. Brooks Interim Chief Financial Officer |
Date: August 12, 2015